Complex Oncology Center Ruse EOOD

The Complex Oncology Center Ruse focuses on preventing and managing cancer-associated thrombosis in patients receiving active cancer treatment. Research aims to reduce clot‑related complications while maintaining effective oncology therapy.

• Evaluation of REGN7508 for thrombosis prevention in solid‑tumor patients
• Assessment of bleeding risk associated with anti‑thrombotic strategies
• Integration of thrombosis outcomes into overall cancer care pathways

This cardiovascular focus complements the site’s broader oncology programs, offering patients comprehensive safety monitoring.

Investigators at the Department of Medical Oncology are advancing therapies for malignant blood disorders, with a particular emphasis on Diffuse Large B‑Cell Lymphoma and follicular lymphoma.

• Combination of BNT327 with standard chemotherapy for lymphoma treatment
• Exploration of Mevrometostat in relapsed/refractory follicular lymphoma
• Biomarker‑driven studies to personalize lymphoid malignancy management

These projects aim to improve response rates and extend survival for patients with aggressive and indolent lymphomas.

A wide range of solid‑tumor studies are conducted at the site, targeting non‑small cell lung cancer and other advanced malignancies to test novel drug combinations and maintenance strategies.

• Niraparib plus pembrolizumab versus placebo as maintenance therapy
• Adagrasib combined with pembrolizumab and chemotherapy for KRAS‑mutated NSCLC
• Zanzalintinib plus pembrolizumab in recurrent head and neck squamous cell carcinoma
• BMS‑986504 with pembrolizumab and chemotherapy in first‑line metastatic NSCLC

The overarching goal is to extend progression‑free and overall survival across diverse tumor types.

The center addresses metabolic complications of cancer, notably cancer cachexia, by evaluating agents that may restore body weight and improve quality of life.

• Ponsegromab versus placebo for weight gain in cachectic patients
• Monitoring of GDF‑15 levels as a metabolic biomarker

These studies seek effective nutritional support that can be integrated with standard oncologic care.

Targeted trials for thoracic malignancies include both non‑small cell and small cell lung cancer, focusing on novel immunotherapy and antibody‑drug conjugates.

• GSK5764227 versus topotecan in relapsed small cell lung cancer
• BMS‑986504 combined with pembrolizumab and chemotherapy for MTAP‑deleted NSCLC
• Evaluation of KRAS‑targeted regimens in advanced NSCLC

The respiratory research agenda strives to improve response durability and reduce treatment‑related toxicity.

Beyond disease‑specific programs, the Complex Oncology Center Ruse conducts interdisciplinary clinical research that spans multiple therapeutic areas and supports innovative trial designs.

• Coordination of 11 active trials with a team of 9 investigators
• Integration of patient‑reported outcomes across studies
• Collaboration with national and international research networks

This comprehensive approach enhances the site’s capacity to bring cutting‑edge therapies to patients in Bulgaria and the broader European region.